Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno

NEW YORK, December 30, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ABEV Research Report: ( http://get.analystsreview.com/pdf/?c=Ambev&d=30-Dec-2014&s=ABEV ),

QVCA Research Report: ( http://get.analystsreview.com/pdf/?c=Liberty%20Interactive&d=30-Dec-2014&s=QVCA ),

IDRA Research Report: ( http://get.analystsreview.com/pdf/?c=Idera&d=30-Dec-2014&s=IDRA ),

ADXSResearch Report: ( http://get.analystsreview.com/pdf/?c=Advaxis&d=30-Dec-2014&s=ADXS ),

JUNOResearch Report: ( http://get.analystsreview.com/pdf/?c=Juno&d=30-Dec-2014&s=JUNO ).

============

--

Analyst Update: FDA Approvals, Dividend Declaration, Service Continuation, and Funding Updates

Reviewed by: Rohit Tuli, CFA®  

The US stock markets on Monday ended the day on a fairly flat note, as gains were curbed when an early rally in energy stocks was lost due to tumbling oil prices. U.S. crude settled down $1.12 at $53.61 a barrel. While the NASDAQ remained flat at 4,806.91, the S&P 500 posted its 53^rd record close of the year on Monday at 2,090.57, up 0.09%. Dow Jones Industrial Average however edged 0.09% lower at 18,038.23. The European stock markets on Monday closed on a mixed note. Greek stocks and bonds slumped after politicians in the country failed for a third time to endorse Prime Minister Antonis Samaras' preferred candidate. Following the rally in the US markets on optimism about the U.S. economic outlook, the Asian stock market rose broadly on Monday. Chinese and Hong Kong shares extended recent gains in reaction to Friday's announcement by the People's Bank of China on easing liquidity requirements at banks starting next year.

In a Board Meeting held of December 22, 2014, Ambev S.A (Ambev) approved a special dividend of BRL0.13 ($0.0481) per share. Shares and ADRs shall be traded ex-dividends as from and including January 2, 2015, the Company said in a regulatory filing. Ambev is a Brazil-based Company engaged in the brewers sector. Read our research report on Ambev to know more about the payout and the Company's stock performance relative to the benchmark.  

Shares of Liberty Interactive Group (Liberty Interactive) gave a muted response to the Board's decision to continue seeking Gregory B. Maffei's services as the President and CEO through 2019. To know more about Liberty Interactive's leadership and its stock performance relative to the benchmark, read our report.

Shares of Idera Pharmaceuticals (Idera) rallied on reports that the U.S. Food and Drug Administration has granted Orphan Designation for its Cancer Treatment. In the last three trading sessions, the stock has gained 16.3%. Shares of the Company ended the December 29, 2014 trading session at $4.50, up almost 13%. Read the financial commentary on Idera, recent FDA approvals and product pipeline in our research report.  

Strong volumes push Advaxis Inc.'s (Advaxis) stock - a clinical-stage biotechnology Company developing cancer immunotherapies, to a new high of $9.75. Recently the Company raised $16.7 million from two institutional investors, to fund its cancer immunotherapy pipeline. Read our research report on Advaxis to know more about the financing agreement and the recent FDA approvals.  

Shares of Seattle-based clinical-stage biopharmaceutical Company - Juno Therapeutics Inc. (Juno) continue their post-IPO run. The Company sold approx. 12.7 million shares raising close to $304 million, which it plans to use for cancer trials and studies. Read more about the Company financials and clinical trial results in our research report on Juno.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED